Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04334993
Other study ID # AYA001
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 1, 2021
Est. completion date May 1, 2025

Study information

Verified date August 2020
Source Israeli Medical Association
Contact Ofir Wolach, MD
Phone +972-3-9378116
Email ofirw@clalit.org.il
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Despite recent therapeutic advancements, the outcome of young adults with Philadelphia-negative (Ph-neg) acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) remains unsatisfactory, especially in those patients with high-risk disease features. In young adults pediatric-based chemotherapy approaches improve outcome. Furthermore, there is evidence that pre-transplant antibody-based therapy may render patients with positive minimal residual disease (MRD+) to an MRD-negative status (MRD-) and that this may be associated with improved post-transplant outcome. This is prospective study to evaluate the potential benefit of a modified pediatric-based approach in young adults with Ph-neg ALL. Safety and efficacy of pre-transplant antibody-based consolidation in high-risk patients with Ph-neg ALL will be performed.


Description:

This is a national, multicenter, phase II clinical trial to evaluate the potential benefit of a modified pediatric-based approach in young adults with Ph-neg ALL. Safety and efficacy of pre-transplant antibody-based consolidation in high-risk patients with Ph-neg ALL will be assessed. Young-adult patients eligible with Ph-neg ALL, LBL and mixed phenotype acute leukemia (MPAL) will undergo risk stratification and started on the pediatric Italian Association of Pediatric Hematology Oncology-Berlin-Frankfurt-Münster (AIEOP-BFM) 2009 protocol. Patients defined as having non-high-risk disease features (non-HR) as defined by MRD and/or cytogenetic criteria will complete the non-HR chemotherapy arm per protocol. Patients designated as having HR disease features after 2 induction blocks will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation. All patients will be centrally assessed for MRD and for Ph-like status.


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date May 1, 2025
Est. primary completion date May 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: 1. Age = 18 years and <30 years of age at the time of signing the informed consent document. 2. Have a documented diagnosis of Ph-neg ALL, LBL or MPAL according to the WHO 2016 classification (appendix I). 3. Females of childbearing potential (FCBP) may participate, providing they meet the following conditions: Agree to use at least two effective contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study, and for 3 months following EOT; and have a negative serum or urine pregnancy test (investigator's discretion; sensitivity at least 25 mIU/mL) at screening; and have a negative serum or urine pregnancy test (investigator's discretion) within 72 hours prior to starting study therapy in the treatment phase (note that the screening serum pregnancy test can be used as the test prior to starting study therapy in treatment phase if it is performed within the 72-hour timeframe). 4. Male subjects with a female partner of childbearing potential must agree to the use of at least two physician-approved contraceptive methods throughout the course of the study and should avoid fathering a child during the course of the study and for 3 months following the last dose of study drug. 5. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted. 6. Able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: 1. Age <18 or over 30 years at the time of signing the informed consent document. 2. Ph-positive disease. 3. Known Human Immunodeficiency Virus (HIV). 4. Known or suspected hypersensitivity to any of the study drugs. 5. Pregnant or lactating females. 6. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 7. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. 8. Participation to an investigational drug trial in the last month before randomization.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Blinatumomab
Patients with high risk disease features after 2 induction blocks as defined per protocol will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation.

Locations

Country Name City State
Israel Rambam Medical Center Haifa
Israel Shaarei Tzedek Medical Center Jerusalem
Israel Rabin Medical Center Petah Tikva
Israel Tel Aviv Medical Center Tel Aviv

Sponsors (1)

Lead Sponsor Collaborator
Israeli Medical Association

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Event-free survival (EFS) Measured from the date of entry on study until treatment failure, relapse from CR, or death from any cause, whichever occurs first 2 years
Secondary Overall survival (OS) Measured from the date of entry on study until until death from any cause 2 years
Secondary Early death during induction Death during the first 60 days from entering study from any cause 60 days
Secondary MRD status MRD status pre- and post-antibody-based therapy MRD will be assess by PCR after induction I (day 33), after induction II (week 12), after blinatumomab therapy (prior to HSCT) and at days 30 and 100 post alloHSCT.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06041490 - Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation Phase 2
Recruiting NCT03978663 - Three Fraction Radiation to Induce Immuno-Oncologic Response N/A
Withdrawn NCT05120622 - Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT05254899 - Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL Phase 2
Recruiting NCT04947098 - Prevent Cancer- Greenville
Recruiting NCT06020443 - Adherence to Lung Cancer Screening by Low-dose Thoracic CT in Haut-Rhin Department, France. N/A
Completed NCT02308280 - Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients Phase 2
Active, not recruiting NCT06046625 - Needs and Preferences of Patients With Head-neck Cutaneous SCC
Recruiting NCT06277050 - Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma Phase 3
Completed NCT03343249 - Adjunctive Smart Phone Based Smoking Cessation Treatment N/A
Recruiting NCT06327568 - Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens
Terminated NCT01941550 - Neoadjuvant Chemotherapy With Cabazitaxel Phase 2
Recruiting NCT05482880 - Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
Recruiting NCT05498272 - Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations Phase 2
Terminated NCT01479192 - Fenretinide in Healthy Young Women at Genetic and Familial Risk Phase 3
Recruiting NCT05557487 - Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration
Recruiting NCT04217356 - Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
Recruiting NCT04740866 - Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer N/A
Recruiting NCT04905329 - A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations
Active, not recruiting NCT01827137 - WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation N/A